Alexander Burnett, MD
Gynecologic Oncology · Little Rock, ARNPI 1225128713
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $179,093 of the $239,233 with a category attached, or 74.9%. Applied Medical Resources Corporation accounts for 99.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $57,729 and has fallen 74.4% since, to $14,776 in 2025.
Across 270 payments — averaging $886.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Applied Medical Resources Corporation$238K
- Coloplast$730
- ANI Pharmaceuticals, Inc.$19
- Myriad Genetic Laboratories, Inc.$16
- Tesaro, Inc.$14
What the payments were for
- Consulting fees$14,8436%
- Speaking & faculty fees$179,09375%
- Travel & lodging$40,17317%
- Food & beverage$5,1102%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Applied Medical Resources Corporation | 260 | $238,453 |
| Coloplast | 7 | $730 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Tesaro, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GelPOINT V-Path$252,508
- GELPOINT VPATH$23,394
- ALTIS$427
How this compares
Too few gynecologic oncology providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 42 | $2,863 |
| Letrozole | 94 | $1,242 |
| Tamoxifen Citrate | 11 | $956 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Little Rock
- Monique SpillmanLittle Rock$2K
- Lawrence BandyLittle Rock$912
- Heather WilliamsLittle Rock$118
- Kristin ZornLittle Rock$50
- John SavageLittle Rock$28
- Joseph IvySpringdale$5K
- Randall HightowerFayetteville$315
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.